MedTrace Logo

Jinhua Qinggan Granules in the Treatment of COVID-19

NCT04723524 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 402

Last updated 2022-06-22

No results posted yet for this study

Summary

The clinical trial is designed to be randomized, double blind, placebo controlled, to evaluate the effectiveness and safety of Jinhua Qinggan granules (JHQG) on mild-category patients of COVID-19 in Pakistani population with the age limit of 18-75 years, at10th day comprehensive follow-up. The informed consent form must be signed by the subjects before their participation in the trial.

Conditions

Interventions

COMBINATION_PRODUCT

Jinhua Qinggan (JHQG) Granules, Traditional Chinese Medicine

Jinhua Qinggan granules: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.

OTHER

Placebo Comparator

Jinhua Qinggan granules simulation (placebo) agent: 5g/sachet; 1 sachet each time, 3 times daily after meal, dissolve in boil water.

Sponsors & Collaborators

  • Indus Hospital and Health Network

    collaborator OTHER

  • Dow University Hospital, Mission Rd, Gulzar-e-Hijri, Scheme 33, Karachi. Tel: (92-21) 38771111

    collaborator UNKNOWN

  • Dr. Ruth K.M. Pfau Civil Hospital, Karachi

    collaborator OTHER_GOV

  • University of Karachi

    lead OTHER

Principal Investigators

  • Muhammad Raza Shah · CBSCR , ICCBS, University of Karachi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-22
Primary Completion
2021-08-23
Completion
2021-08-23

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04723524 on ClinicalTrials.gov